Spinal Cord Injury Fact Sheet

CIRM funds many projects seeking to better understand spinal cord injury and to translate those discoveries into new therapies.

Description

About 250,000 people in the U.S. live with spinal cord injuries. Half of those are quadriplegic, with the paralysis impacting all four limbs to some extent. For those individuals the lifetime cost of managing their condition is estimated to be between $2 million and $3 million.

Spinal cord injury became the first condition targeted in a human clinical trial using cells made from embryonic stem cells. That trial, begun by Geron in 2010 and based on the findings of a team CIRM currently funds, was later cancelled by Geron for financial reasons. By the time of the cancellation five patients around the country had been enrolled in the study, including two at Stanford, who entered the trial during a period when CIRM funded Geron. Those patients continue to be followed to learn as much as possible about this approach.

California’s stem cell agency retains many grants for research to move potential spinal cord injury therapies forward (the full list is below). Much of this work focuses on trying to determine which type of nerve cell is the best one to transplant, and deciding which type of stem cell is the best starting point for making those cells. Other research is trying to see if these transplanted cells become part of the existing nerve system, helping create new pathways that can transmit nerve signals to muscles. The researchers are also looking at ways to try and improve the ability of these transplanted cells to become part of the nerve system.

One obstacle that some teams are trying to overcome is the tendency of the scar at the site of injury to block the growth of these transplanted cells. One group is trying to overcome that by combining stem cells with synthetic scaffolds that can be placed at the site of injury, to help the cells bridge the scar and restore signals. In animal models this combination has resulted in an increase in mobility compared to stem cell grafts alone.

Clinical Stage Programs

Asterias Biotherapeutics

The company uses cells derived from embryonic stem cells to heal the spinal cord at the site of injury. They mature the stem cells into cells called oligodendrocyte precursor cells that are injected at the site of injury where it is hoped they can repair the insulating layer, called myelin, that normally protects the nerves in the spinal cord. 


 
Progress and Promise toward a stem cell-based therapy for spinal cord injury

CIRM Grants Targeting Spinal Cord Injury

Researcher name Institution Grant Title Grant Type Approved funds
Catriona Jamieson University of California, San Diego Alpha Stem Cell Clinic for the Development of Regenerative Therapies Alpha Stem Cell Clinics $7,999,137
Bennett Novitch University of California, Los Angeles Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons Basic Biology I $1,229,922
Sarah Heilshorn Stanford University Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System Tools and Technologies III $1,347,767
Aileen Anderson University of California, Irvine Role of the microenvironment in human iPS and NSC fate and tumorigenesis Basic Biology II $1,256,194
Leif Havton University of California, Los Angeles Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons Early Translational II $75,628
leif Havton University of California, Irvine Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons Early Translational II $1,527,011
Leif Havton University of California, Los Angeles Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases Tools and Technologies III $1,308,711
Binhai Zheng University of California, San Diego Genetic manipulation of human embryonic stem cells and its application in studying CNS development and repair SEED Grant $600,441
David Schaffer University of California, Berkeley Scalable, Defined Production of Oligodendrocyte Precursor Cells to Treat Neural Disease and Injury Quest - Discovery Stage Research Projects $1,634,055
Brian Cummings University of California, Irvine The Immunological Niche: Effect of immunosuppressant drugs on stem cell proliferation, gene expression, and differentiation in a model of spinal cord injury. SEED Grant $595,345
Ziwei Huang Sanford-Burnham Medical Research Institute New Chemokine-Derived Therapeutics Targeting Stem Cell Migration SEED Grant $708,000
Hans Keirstead University of California, Irvine hESC-Derived Motor Neurons For the Treatment of Cervical Spinal Cord Injury Comprehensive Grant $2,158,445
Martin Marsala University of California, San Diego Spinal ischemic paraplegia: modulation by human embryonic stem cell implant. Comprehensive Grant $2,356,090
Martin Marsala University of California, San Diego Induction of immune tolerance after spinal grafting of human ES-derived neural precursors Transplantation Immunology $1,387,800
Jane Lebkowski Geron Corporation Evaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury Targeted Clinical Development $6,405,771
Arnold Kriegstein University of California, San Francisco Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury Early Translational III $1,623,251
Mark Tuszynski University of California, San Diego Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury Early Translational III $4,600,447
Eric Ahrens University of California, San Diego Molecular Imaging for Stem Cell Science and Clinical Application Research Leadership $5,920,899
Samantha Butler University of California, Los Angeles Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate Basic Biology V $515,730
Jane Lebkowski Asterias Biotherapeutics A Phase I/IIa Dose Escalation Safety Study of AST-OPC1 in Patients with Cervical Sensorimotor Complete Spinal Cord Injury Strategic Partnership III Track A $14,323,318
Total:
$57,573,962.00

CIRM Spinal Cord Injury Videos

Resources

Find Out More:
Stem Cell FAQ | Stem Cell Videos | What We Fund